"name","documentVersion","studyInvestigationalInterventions","label","uuid:ID","studyEstimands","bcCategories","id","description","studyDesignRationale"
"Study Design 1","","[]","","faa8a6b2-7181-4c41-8d8c-0563b4326f67","[]","[]","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
